Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 1963-1967

  Livi, Riccardo ^a   Guiducci, Serena ^a   Perfetto, Federico ^a   Ciuti, Gabriele ^a   Grifoni, Elisa ^a   Conforti, Letizia ^a   Galluccio, Felice ^a   Pignone, Alberto Moggi ^a   Cerinic, Marco Matucci ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYCHLOROQUINE; ILOPROST; LEVOTHYROXINE; PROSTAGLANDIN E;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE DURATION; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; MALE; MICROALBUMINURIA; PREDICTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAYNAUD PHENOMENON; RENAL FUNCTIONAL RESERVE; RENAL SYSTEM PARAMETERS; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 80053568473     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.152892     Document Type: Article

References (47)

1. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22:861-78. (Pubitemid 26396055)
2. Walker JG, Ahern MJ, Smith MD, et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 2003;33:216-20. (Pubitemid 36718377)
3. Denton CP, Black CM. Scleroderma-clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.
4. Steen V D, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7. (Pubitemid 20262820)
5. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008;20:692-6.
6. Kovalchik M T, Guggenheim SJ, Silverman MH, et al. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978;89:881-7. (Pubitemid 9050988)
7. Trostle D C, Bedetti CD, Steen VD, et al. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 1988;31:393-400. (Pubitemid 18091662)
8. Black C M, Duance VC, Sims TJ, et al. An investigation of the biochemical and histological changes in the collagen of the kidney and skeletal muscle in systemic sclerosis. Coll Relat Res 1983;3:231-43.
9. Cannon P J, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 1974;53:1-46.
10. Clements P J, Lachenbruch PA, Furst DE, et al. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 1994;37:67-74. (Pubitemid 24027695)
11. Rivolta R, Mascagni B, Berruti V, et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum 1996;39:1030-4. (Pubitemid 26182073)
12. Bulpitt K J, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602-9. (Pubitemid 23102694)
13. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:252-60.
14. Livi R, Teghini L, Pignone A, et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002;61:682-6. (Pubitemid 34787704)
15. Meyer T W, Ichikawa I, Zatz R, et al. The renal hemodynamic response to amino acid infusion in the rat. Trans Assoc Am Physicians 1983;96:76-83.
16. Chan A Y, Cheng ML, Keil LC, et al. Functional response of healthy and diseased glomeruli to a large, protein-rich meal. J Clin Invest 1988;81:245-54. (Pubitemid 18092260)
17. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990;8:561-5.
18. La Civita L, Rossi M, Vagheggini G, et al. Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann Rheum Dis 1998;57:52-5. (Pubitemid 28175222)
19. Cailes J, Winter S, Du Bois RM, et al. Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. Chest 1998;114:178-84. (Pubitemid 28337381)
20. Montisci R, Vacca A, Garau P, et al. D etection of early impairment of coronary fl ow reserve in patients with systemic sclerosis. Ann Rheum Dis 2003;62:890-3. (Pubitemid 37026502)
21. LeRoy E C, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classifi cation, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
22. Fogazzi GB. Urinalysis and microscopy . In:Davison AM, Cameron JS, Grunfeld J-P, Kerr DNS, Ritz E, Winearls CG, eds . Oxford Textbook of Clinical Nephrology . Third Edition . Volume 1. New York, NY, USA:Oxford University Press Inc. 2005:25.
23. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537.
24. Steen V D, Mayes MD, Merkel PA. Assessment of kidney involvement. C lin Exp Rheumatol 2003;21(3 Suppl 29):S29-31.
25. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007;25:1751-62.
26. Shanmugam VK, Steen VD. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010;2010:pii:538589.
27. Steen V D, Syzd A, Johnson JP, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005;32:649-55. (Pubitemid 40524696)
28. Scheja A, Bartosik I, Wuttge DM, et al. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009;38:295-8.
29. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. (Pubitemid 36043346)
30. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
31. National Kidney Foundation. K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classifi cation, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
32. Levey A S, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100. (Pubitemid 41623371)
33. Rahn KH, Heidenreich S, Brückner D. How to assess glomerular function and damage in humans. J Hypertens 1999;17:309-17. (Pubitemid 29116637)
34. Bosch J P, Saccaggi A, Lauer A, et al. Renal functional reserve in humans. Effect of protein intake on glomerular fi ltration rate. Am J Med 1983;75:943-50. (Pubitemid 14204584)
35. Locke I C, Worrall JG, Leaker B, et al. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997;24:86-9. (Pubitemid 27059863)
36. Yamashita K, Yorioka N, Kyuden Y, et al. A case of CREST syndrome and myeloperoxidase-specifi c anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin Nephrol 2000;53:296-300. (Pubitemid 30204938)
37. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485-94. (Pubitemid 47241915)
38. Bunn C C, Denton CP, Shi-Wen X, et al. Anti-RNA polymerases and other autoantibody specifi cities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
39. Medsger TA, Jr . Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
40. Kingdon E J, Knight CJ, Dustan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 2003;42:26-33. (Pubitemid 36131563)
41. Seiberlich B, Hunzelmann N, Krieg T, et al. Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity. Clin Nephrol 2008;70:110-17.
42. Batal I, Domsic RT, Medsger TA, et al. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010;2010:543704.
43. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249(3 Pt 2):F324-37. (Pubitemid 16225762)
44. Hoy W E, Hughson MD, Bertram JF, et al. Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol 2005;16:2557-64.
45. Bakris G L, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
46. Scorza R, Rivolta R, Mascagni B, et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997;24:1944-8. (Pubitemid 27431926)
47. Airò P, Rossi M, Scarsi M, et al. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol 2007;25:722-7. (Pubitemid 350284844)